These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 33112684)

  • 1. Oral Contraceptive Types in Relation to ABO Blood Groups Among Saudi Women of Different Reproductive Age Groups and Impact on Venous Thromboembolism.
    Mohamed ABO; Al-Ama N; Al Kreathy H; Ahmed KHB; Al Amri T; Harakeh S; Mousa SA; De Laat B
    Clin Appl Thromb Hemost; 2020; 26():1076029620966051. PubMed ID: 33112684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
    Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
    Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of oral contraceptives on hemostasis and thrombosis.
    Rosing J; Tans G
    Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S375-82. PubMed ID: 10368524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of oral contraceptive usage on thrombin generation and activated protein C resistance in Saudi women, with a possible impact of the body mass index.
    Mohamed ABO; Kelchtermans H; Konings J; van Daal J; Al Marzouki A; Harakeh S; de Laat B
    PLoS One; 2018; 13(10):e0206376. PubMed ID: 30359453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The risks of venous thromboembolic disease among German women using oral contraceptives: a database study.
    Farmer RD; Todd JC; Lewis MA; MacRae KD; Williams TJ
    Contraception; 1998 Feb; 57(2):67-70. PubMed ID: 9589831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism.
    Heinemann LA; Assmann A; Spannagl M; Schramm W; Dick A; Kluft C; de Maat MP
    Contraception; 1998 Nov; 58(5):321-2. PubMed ID: 9883389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography.
    Tchaikovski SN; van Vliet HA; Thomassen MC; Bertina RM; Rosendaal FR; Sandset PM; Helmerhorst FM; Tans G; Rosing J
    Thromb Haemost; 2007 Dec; 98(6):1350-6. PubMed ID: 18064335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-time use of newer oral contraceptives and the risk of venous thromboembolism.
    Suissa S; Blais L; Spitzer WO; Cusson J; Lewis M; Heinemann L
    Contraception; 1997 Sep; 56(3):141-6. PubMed ID: 9347203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 1995 pill scare revisited: anatomy of a non-epidemic.
    Spitzer WO
    Hum Reprod; 1997 Nov; 12(11):2347-57. PubMed ID: 9436662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Smoking and use of oral contraceptives: impact on thrombotic diseases.
    Lidegaard O
    Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S357-63. PubMed ID: 10368521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen and progestin components of oral contraceptives: relationship to vascular disease.
    Carr BR; Ory H
    Contraception; 1997 May; 55(5):267-72. PubMed ID: 9220222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
    Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Büller HR; Vandenbroucke JP
    Lancet; 1995 Dec; 346(8990):1593-6. PubMed ID: 7500751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Third-generation oral contraceptives: how risky?
    Weiss N
    Lancet; 1995 Dec; 346(8990):1570. PubMed ID: 7500743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.
    Rosing J; Middeldorp S; Curvers J; Christella M; Thomassen LG; Nicolaes GA; Meijers JC; Bouma BN; Büller HR; Prins MH; Tans G
    Lancet; 1999 Dec; 354(9195):2036-40. PubMed ID: 10636369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives.
    Alhenc-Gelas M; Plu-Bureau G; Guillonneau S; Kirzin JM; Aiach M; Ochat N; Scarabin PY
    J Thromb Haemost; 2004 Sep; 2(9):1594-600. PubMed ID: 15333036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis.
    Manzoli L; De Vito C; Marzuillo C; Boccia A; Villari P
    Drug Saf; 2012 Mar; 35(3):191-205. PubMed ID: 22283630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk of venous thromboembolism in users of postcoital contraceptive pills.
    Vasilakis C; Jick SS; Jick H
    Contraception; 1999 Feb; 59(2):79-83. PubMed ID: 10361621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of thrombotic risk factors when oral contraceptives are prescribed. A control-only study.
    Lidegaard O
    Acta Obstet Gynecol Scand; 1997 Mar; 76(3):252-60. PubMed ID: 9093141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral contraceptives and thrombotic disease: risk of venous thromboembolism.
    Helmerhorst FM; Bloemenkamp KW; Rosendaal FR; Vandenbroucke JP
    Thromb Haemost; 1997 Jul; 78(1):327-33. PubMed ID: 9198174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemostatic effects of third- and second-generation oral contraceptives: absence of a causal mechanism for a difference in risk of venous thromboembolism.
    Winkler UH
    Contraception; 2000 Aug; 62(2 Suppl):11S-20S; discussion 37S-38S. PubMed ID: 11102598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.